Published in Pediatr Infect Dis J on May 01, 2005
Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. Proc Natl Acad Sci U S A (2011) 1.61
What is new in pertussis? Eur J Pediatr (2007) 1.52
The estimated incidence of pertussis in people aged 50 years old in the United States, 2006-2010. BMC Infect Dis (2015) 1.44
Evidence of Bordetella pertussis infection in vaccinated 1-year-old Danish children. Eur J Pediatr (2010) 1.40
The epidemiology of pertussis in Germany: past and present. BMC Infect Dis (2009) 1.31
Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog (2006) 1.26
The Bps polysaccharide of Bordetella pertussis promotes colonization and biofilm formation in the nose by functioning as an adhesin. Mol Microbiol (2010) 1.25
Deciphering the impacts of vaccination and immunity on pertussis epidemiology in Thailand. Proc Natl Acad Sci U S A (2013) 1.15
Accelerating control of pertussis in England and Wales. Emerg Infect Dis (2012) 1.15
Can vaccine legacy explain the British pertussis resurgence? Vaccine (2013) 1.09
Immunosenescence and novel vaccination strategies for the elderly. Front Immunol (2013) 1.07
Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev (2016) 1.07
The seroepidemiology of immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study. BMC Infect Dis (2012) 1.03
Bordetella pertussis clones identified by multilocus variable-number tandem-repeat analysis. Emerg Infect Dis (2010) 1.03
Age-specific sex-related differences in infections: a statistical analysis of national surveillance data in Japan. PLoS One (2012) 0.98
Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model. PLoS One (2010) 0.98
Pertussis: a review of disease epidemiology worldwide and in Italy. Int J Environ Res Public Health (2012) 0.93
Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin Vaccine Immunol (2009) 0.91
Vaccination coverage among adolescents and risk factors associated with incomplete immunization. Eur J Pediatr (2011) 0.90
The disease burden of pertussis in adults 50 years old and older in the United States: a retrospective study. BMC Infect Dis (2013) 0.88
Pertussis prevalence and its determinants among children with persistent cough in urban Uganda. PLoS One (2015) 0.85
Should the pertussis case definition for public health reporting be refined? J Public Health Manag Pract (2009) 0.83
Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (WCV). PLoS One (2010) 0.81
High prevalence of Bordetella pertussis in children under 5 years old hospitalized with acute respiratory infections in Lima, Peru. BMC Infect Dis (2015) 0.80
Modelling the impact of extended vaccination strategies on the epidemiology of pertussis. Epidemiol Infect (2011) 0.80
Epidemiological characteristics of pertussis in Estonia, Lithuania, Romania, the Czech Republic, Poland and Turkey-1945 to 2005. Eur J Pediatr (2008) 0.80
Hospitalizations for pertussis in Italy, 1999-2009: analysis of the hospital discharge database. Eur J Pediatr (2012) 0.80
Detection of Bordetella pertussis in Infants Suspected to have Whooping Cough. Open Respir Med J (2012) 0.79
Pertussis knowledge, attitude and practices among European health care professionals in charge of adult vaccination. Hum Vaccin (2011) 0.79
Recent findings on pertussis epidemiology in Turkey. Eur J Clin Microbiol Infect Dis (2008) 0.78
Resident microbiota affect Bordetella pertussis infectious dose and host specificity. J Infect Dis (2013) 0.78
Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccine. Hum Vaccin Immunother (2016) 0.77
Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis. Clin Infect Dis (2016) 0.77
Pertussis Epidemiology in Greece and Emerging Risk Groups during the Vaccination Era (1980-2008). Adv Prev Med (2012) 0.75
Whooping cough dynamics in Chile (1932-2010): disease temporal fluctuations across a north-south gradient. BMC Infect Dis (2015) 0.75
Assessment of antibody level and avidity against Bordetella pertussis in a cohort of Egyptian individuals aged 1-18 years. J Adv Res (2015) 0.75
Pertussis infection in a baccalaureate nursing program: clinical implications, emerging issues, and recommendations. J Contin Educ Nurs (2008) 0.75
Antibody response from whole-cell pertussis vaccine immunized Brazilian children against different strains of Bordetella pertussis. Am J Trop Med Hyg (2010) 0.75
Seroprevalence of Bordetella pertussis specific Immunoglobulin G antibody levels among asymptomatic individuals aged 4 to 24 years: a descriptive cross sectional study from Sri Lanka. BMC Infect Dis (2016) 0.75
Rediscovering Pertussis. Front Pediatr (2016) 0.75
Pertussis Incidence by Time, Province and Age Group in Iran, 2006-2011. Iran J Public Health (2016) 0.75
The distribution over time of costs and social net benefits for pertussis immunization programs. Int J Health Care Finance Econ (2009) 0.75
Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory‐confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis (2010) 2.41
Chagas' cardiomyopathy: the economic burden of an expensive and neglected disease. Int J Cardiol (2013) 1.98
Myocardial perfusion imaging is a strong predictor of death in women. JACC Cardiovasc Imaging (2011) 1.45
ORS during the 2000-2001 influenza vaccination season. Can Commun Dis Rep (2002) 1.38
18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med (2010) 1.31
Contagious period for pandemic (H1N1) 2009. Emerg Infect Dis (2010) 1.28
Pertussis immunization in the global pertussis initiative international region: recommended strategies and implementation considerations. Pediatr Infect Dis J (2005) 1.22
The need for validation of statistical methods for estimating respiratory virus-attributable hospitalization. Am J Epidemiol (2009) 1.13
Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine (2011) 1.11
Neisseria meningitidis carriage during an outbreak of serogroup C disease. Clin Infect Dis (2003) 1.05
Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol (2010) 0.96
Canadian Association for Immunization Research and Evaluation (CAIRE) guidelines for industry-sponsored clinical trial and epidemiology contract research. Hum Vaccin (2005) 0.93
Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions. Clin Lymphoma Myeloma Leuk (2011) 0.85
Economic burden of pertussis and the impact of immunization. Pediatr Infect Dis J (2005) 0.84
Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations. Pediatr Infect Dis J (2005) 0.83
Longitudinal analysis of genotype distribution of influenza A virus from 2003 to 2005. J Clin Microbiol (2006) 0.77
Evaluation of surgical treatment of congenital heart disease in patients aged above 16 years. Arq Bras Cardiol (2012) 0.76
TBNA or EBUS-TBNA? That is the question. Arch Bronconeumol (2011) 0.75
Regrettable lack of definition of the "well tolerated" vaccine. Vaccine (2010) 0.75
The high impact of an influenza pandemic. CMAJ (2004) 0.75